Capricor Therapeutics (CAPR) Misses Q1 EPS by 7c

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.59), $0.07 worse than the analyst estimate of ($0.52).

Guidance

Financial Outlook: The Company believes that, based on the current operating plan and financial resources, its available cash, cash equivalents and marketable securities will be sufficient to cover anticipated expenses and capital requirements through Q4 2027. This outlook excludes any potential revenue from product sales, the potential monetization of a PRV, if received, or other non-operating sources of capital.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Popular stocks with increasing option volume: SPCX MSTR PLTR MU HOOD MRNA SOFI BABA INTC WMT
• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance